Effective suppression of parathyroid hormone by 1α-hydroxy-vitamin D2 in hemodialysis patients with moderate to severe secondary hyperparathyroidism

Kidney International

Volumn 51, Issue 1, 1997, Pages 317-323

  Tan Jr , Alexander U ^a   Levine, Barton S ^c   Mazess, Richard B ^c   Kyllo, Darlene M ^c   Bishop, Charles W ^c   Knutson, Joyce C ^c   Kleinman, Kenneth S ^c   Coburn, Jack W ^b  

^a Lake Charles Memorial Hospital   (United States)

^b VETERANS AFFAIRS MEDICAL CENTER   (United States)

^c NONE

Author keywords

[No Author keywords available]

Indexed keywords

CALCITRIOL; DOXERCALCIFEROL; PARATHYROID HORMONE;

ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; HEMODIALYSIS; HUMAN; MULTICENTER STUDY; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; SECONDARY HYPERPARATHYROIDISM;

EID: 8044230723     PISSN: 00852538     EISSN: None     Source Type: Journal    
DOI: 10.1038/ki.1997.39     Document Type: Article

References (35)

1. JARA A, BOVER J, FELSENFELD A, NEMEH M, LEVINE BS: Divalent ion metabolism, in Current Nephrology, edited by GONICK HC, 1996, p 133
2. SILVER J, RUSSELL J, SHERWOOD LM: Regulation by vitamin D metabolites of messenger ribonucleic acid for preproparathyroid hormone in isolated bovine parathyroid cells. Proc Nat Acad Sci USA 82:4270-4273, 1985
3. 3 of transcription of the parathyroid hormone gene. Endocrinol 119: 2864-2866, 1986
4. BROWN AJ, RITTER CR, FINCH JL, MORRISSEY J, MARTIN KJ, MURAYAMA E, NISHII Y, SLATOPOLSKY E: The noncalcemic analogue of vitamin D, 22-oxacalcitriol, suppresses parathyroid hormone synthesis and secretion. J Clin Invest 84:728-732, 1989
5. 2, suppresses parathyroid hormone secretion in uremic rats in the absence of hypercalcemia. Am J Kidney Dis 26:852-860, 1995
6. MORII H, MIURA Y, NAGURA Y, KAWAGUCHI Y, OGURA Y, IMAMURA N, SHOJI R, TSUKAMOTO Y, KIJIMA Y, SUZUKI M, OHKI K, NISHITANI H, INOUE T, ONO T, FUKUNAGA M, OSAWA G, HEXAFLURO D3 RESEARCH COMMITTEE: Effect of hexafluorocalcitriol on renal osteodystrophy in hemodialysed patients. Nephrol Dial Transplant 11: 1204, 1996
7. SJÖDEN G, LINDGREN JU, DELUCA HF: Antirachitic activity of 1α-hydroxyergocalciferol and 1α-hydroxycholecalciferol in rats. J Nutr 114:2043-2046, 1984
8. 3 in the rat. Proc Soc Exp Biol Med 178:432-436, 1985
9. 2 analogs on calcium metabolism in vitamin D-deficient rats and in MC3T3 osteoblastic cells. Res Exp Med 191:235-242, 1991
10. 2 on calcium homeostasis in postmenopausal osteopenic women. J Bone Miner Res 9:607-614, 1994
11. SHERRARD DJ, HERCZ G, PEI Y, MALONEY NA, GREENWOOD C, MANUEL A, SAIPHOO C, FENTON SS, SEGRE GV: The spectrum of bone disease in end-stage renal failure - An evolving disorder. Kidney Int 43:436-435, 1993
12. SOLAL MC, SEBERT JL, BOUDAILLIEZ B, ANNICK M, MORINIERE P, GUERIS J, BOUILLON R, FOURNIER A: Comparison of intact, midregion, and carboxy terminal assays of parathyroid hormone for the diagnosis of bone disease in hemodialyzed patients. J Clin Endocrinol Metab 73:516-524, 1991
13. QUARLES LD, LOBAUGH B, MURPHY G: Intact parathyroid hormone overestimates the presence and severity of parathyroid-mediated osseous abnormalities in uremia. J Clin Endocrinol Metab 75:145-150, 1992
14. SEGRE GV, SHERRARD DJ, CARLTON EI: Use of the PTH (IRMA) Assay in Patients with Impaired Renal Function and Renal Osteodystrophy. San Juan Capistrano, Nichols Institute, 1990, p 1
15. GLANTZ SA: Primer of Biostatistics (2nd ed). New York, McGraw Hill, Inc., 1987
16. FISCHER ER, HARRIS DCH: Comparison of intermittent oral and intravenous calcitriol in hemodialysis patients with secondary hyperparathyroidism. Clin Nephrol 40:216-220, 1993
17. HERRMANN P, RITZ E, SCHMIDT-GAYK H, SCHÄFER I, GEYER J, NONNAST-DANIEL B, KOCH K-M, WEBER U, HÖRL W, HAAS-WÖRLE A, KÜHN K, BIERTHER B, SCHNEIDER P: Comparison of intermittent and continuous oral administration of calcitriol in dialysis patients: A randomized prospective trial. Nephron 67:48-53, 1994
18. ANDRESS DL, NORRIS KC, COBURN JW, SLATOPOLSKY EA, SHERRARD DJ: Intravenous calcitriol in the treatment of refractory osteitis fibrosa of chronic renal failure. N Engl J Med 321:274-279, 1989
19. 3 pulse therapy' in hemodialysis patients with severe secondary hyperparathroidism. Nephron 57:23-28, 1991
20. CANNELLA G, BONUCCI E, ROLLA D, BALLANTI P, MORIERO E, DE GRANDI R, AUGERI C, CLAUDIANI F, DI MAIO G: Evidence of healing of secondary hyperparathyroidism in chronically hemodialyzed uremic patients treated with long-term intravenous calcitriol. Kidney Int 46:1124-1132, 1994
21. RODRIGUEZ M, FELSENFELD AJ, WILLIAMS C, PEDERSON JA, LLACH F: The effect of long-term calcitriol administration on parathyroid function in hemodialysis patients. J Am Soc Nephrol 2:1014-1020, 1991
22. MALBERTI F, SURIAN M, COSCI P: Effect of chronic intravenous calcitriol on parathyroid function and set point of calcium in dialysis patients with refractory secondary hyperparathyroidism. Nephrol Dial Transplant 7:822-828, 1992
23. LLACH F, HERVAS J, CEREZO S: The importance of dosing intravenous calcitriol in dialysis patients with severe hyperparathyroidism. Am J Kidney Dis 26:845-851, 1995
24. LEVINE BS, SONG MM: Pharmacokinetics and efficacy of pulse oral versus intravenous calcitriol in hemodialysis patients. J Am Soc Nephrol 7:488-496, 1996
25. GALLIENI M, BRANCACCIO D, PADOVESE P, ROLLA D, BEDANI P, COLANTONIO G, BRONZIERI C, BAGNI B, TAROLO G, ITALIAN GROUP FOR THE STUDY OF INTRAVENOUS CALCITRIOL: Low-dose intravenous calcitriol treatment of secondary hyperparathyroidism in hemodialysis patients. Kidney Int 42:1191-1198, 1992
26. SPRAGUE SM, MOE SM: Safety and efficacy of long-term treatment of secondary hyperparathyroidism by low-dose intravenous calcitriol. Am J Kidney Dis 19:532-539, 1992
27. QUARLES LD, YOHAY DA, CARROLL BA, SPRITZER CE, MINDA SA, BARTHOLOMAY D, LOBAUGH BA: Prospective trial of pulse oral versus intravenous calcitriol treatment of hyperparathyroidism in ESRD. Kidney Int 45:1710-1721, 1994
28. OETTINGER CW, OLIVER JC, MACON EJ: The effects of calcium carbonate as the sole phosphate binder in combination with low calcium dialysate and calcitriol therapy in chronic dialysis patients. J Am Soc Nephrol 3:995-1001, 1992
29. 3 and 22-oxacalcitriol on phosphate and calcium metabolism. Kidney Int 43:561-566, 1993
30. GONELLA M, CALABRESE G, ALEO AG, VAGELLI G, DEAMBROGIO P: Calcitriol pulse therapy for severe hyperparathyroidism or calcium salts as phosphate binders in renal dialysis patients. Nephron 71:350-353, 1995
31. DRESSLER R, LAUT J, LYNN RI, GINSBERG N: Long-term high dose intravenous calcitriol therapy in end-stage renal disease patients with severe secondary hyperparathyroidism. Clin Nephrol 43:324-331, 1995
32. 3 on secondary hyperparathyroidism in chronic uremic patients on maintenance hemodialysis. Nephron 53:194-200, 1989
33. LJUNGHALL S, ALTHOFF P, FELLSTRÖM B, MARJANOVIC B, NISELL J, WEISS L, WIDE L: Effects on serum parathyroid hormone of intravenous treatment with alphacalcidol in patients on chronic hemodialysis. Nephron 55:380-385, 1990
34. 3 and low dialysate calcium. Kidney Int 43(Suppl 41):S121-S124, 1993
35. SLATOPOLSKY E, WEERTS C, THIELAN J, HORST RL, HARTER H, MARTIN KJ: Marked suppression of secondary hyperparathyroidism by intravenous administration of 1,25-dihydroxycholecalciferol in uremic patients. J Clin Invest 74:2136-2143, 1984